Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Authors

  • Dr Sanjay Kalra Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
  • Dr Saptarshi Bhattacharya Dept. of Endocrinology, Apollo Indraprastha Hospital, New Delhi, India
  • Dr Shehla Shaikh Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

Keywords:

Gluconeogenesis,, imeglimin, oxidative, phosphorylation, inhibitor,, mitochondria, pharmacotherapeutics, type 2 diabetes mellitus

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Downloads

Published

2022-10-13

Issue

Vol. 33 No. 5 (2022)

Section

Guest Editorial

How to Cite

Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics. (2022). Indian Journal Of Clinical Practice, 33(5), 8-10. https://ojs.ijcp.in/index.php/IJCP/article/view/305

Similar Articles

1-10 of 180

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 4 > >>